Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study — Marco Proietti (2020) | RDL Network
Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study
Article 2020 en
Authors
MP
Marco Proietti
IM
Irene Marzona
TV
Tommaso Vannini
Abstract
1 min read
In AF patients, concomitant LD carries a significantly higher risk for all clinical outcomes. Use of OAC in AF patients with LD was associated with a significant favourable benefit/risk ratio, even in high-risk patient subgroups.
Discussion(0)
No comments yet. Be the first to comment.